Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies

被引:35
|
作者
Pan, Wei [1 ]
Kang, Yongbo [2 ,3 ]
机构
[1] Kunming Univ Sci & Technol, Fac Foreign Languages & Cultures, Kunming, Yunnan, Peoples R China
[2] Kunming Univ Sci & Technol, Fac Med, Kunming, Yunnan, Peoples R China
[3] Kunming Univ Sci & Technol, Genet & Pharmacogen Lab, Kunming, Yunnan, Peoples R China
关键词
Chronic kidney disease (CKD); Intestinal microbiota; Uremic toxins; Lipopolysaccharides (LPS); Immune deregulation; Prebiotic; Probiotics; STAGE RENAL-DISEASE; P-CRESYL SULFATE; SIZED POLYETHYLENE-GLYCOLS; HUMAN COLONIC MICROBIOTA; GLUCAGON-LIKE PEPTIDE-1; TRIMETHYLAMINE-N-OXIDE; BOUND UREMIC TOXINS; INDOXYL SULFATE; HEMODIALYSIS-PATIENTS; CARDIOVASCULAR-DISEASE;
D O I
10.1007/s11255-017-1689-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The complicated communities of microbiota colonizing the human gastrointestinal tract exert a strong function in health maintenance and disease prevention. Indeed, accumulating evidence has indicated that the intestinal microbiota plays a key role in the pathogenesis and development of chronic kidney disease (CKD). Modulation of the gut microbiome composition in CKD may contribute to the accumulation of gut-derived uremic toxins, high circulating level of lipopolysaccharides and immune deregulation, all of which play a critical role in the pathogenesis of CKD and CKD-associated complications. In this review, we discuss the recent findings on the potential impact of gut microbiota in CKD and the underlying mechanisms by which microbiota can influence kidney diseases and vice versa. Additionally, the potential efficacy of pre-, pro- and synbiotics in the restoration of healthy gut microbia is described in detail to provide future directions for research.
引用
收藏
页码:289 / 299
页数:11
相关论文
共 50 条
  • [21] Modulation of the Gut Microbiota by Resistant Starch as a Treatment of Chronic Kidney Diseases: Evidence of Efficacy and Mechanistic Insights
    Snelson, Matthew
    Kellow, Nicole J.
    Coughlan, Melinda T.
    ADVANCES IN NUTRITION, 2019, 10 (02) : 303 - 320
  • [22] Gut microbiota and probiotics intervention: A new therapeutic target for management of chronic kidney disease
    Zhu, Han
    Yao, Ying
    CHINESE SCIENCE BULLETIN-CHINESE, 2019, 64 (03): : 291 - 297
  • [23] The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease
    Tao Yang
    Elaine M. Richards
    Carl J. Pepine
    Mohan K. Raizada
    Nature Reviews Nephrology, 2018, 14 : 442 - 456
  • [24] The gut microbiome tango in the progression of chronic kidney disease and potential therapeutic strategies
    Zijing Tang
    Shiyan Yu
    Yu Pan
    Journal of Translational Medicine, 21
  • [25] The gut microbiome tango in the progression of chronic kidney disease and potential therapeutic strategies
    Tang, Zijing
    Yu, Shiyan
    Pan, Yu
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [26] Gut Microbiota Dysbiosis in Systemic Lupus Erythematosus: Novel Insights into Mechanisms and Promising Therapeutic Strategies
    Pan, Quanren
    Guo, Fengbiao
    Huang, Yanyan
    Li, Aifen
    Chen, Shuxian
    Chen, Jiaxuan
    Liu, Hua-feng
    Pan, Qingjun
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [28] Insights into the gut-kidney axis and implications for chronic kidney disease management in cats and dogs
    Summers, Stacie
    Quimby, Jessica
    VETERINARY JOURNAL, 2024, 306
  • [29] Dysbiosis of Gut Microbiota in Patients with Chronic Kidney Disease
    Yasuno, Tetsuhiko
    Takahashi, Koji
    Tada, Kazuhiro
    Hiyamuta, Hiroto
    Watanabe, Maho
    Ito, Kenji
    Arima, Hisatomi
    Masutani, Kosuke
    INTERNAL MEDICINE, 2024, 63 (03) : 347 - 352
  • [30] Gut microbiota and inflammation in chronic kidney disease patients
    Mafra, Denise
    Fouque, Denis
    CLINICAL KIDNEY JOURNAL, 2015, 8 (03) : 332 - 334